Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial

Ferlay, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 Balogh, 2016, Hepatocellular carcinoma: a review, J Hepatocell Carcinoma, 3, 41, 10.2147/JHC.S61146 Llovet, 2008, Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 378, 10.1056/NEJMoa0708857 Finn, 2020, Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma, N Engl J Med, 382, 1894, 10.1056/NEJMoa1915745 Lau, 1994, Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study, Br J Cancer, 70, 994, 10.1038/bjc.1994.436 Dancey, 2000, Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres, J Nucl Med, 41, 1673 Benson, 2019, Guidelines insights: hepatobiliary cancers, version 2. 2019, J Natl Compr Canc Netw, 17, 302, 10.6004/jnccn.2019.0019 Vogel, 2019, Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 30, 871, 10.1093/annonc/mdy510 Salem, 2010, Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes, Gastroenterology, 138, 52, 10.1053/j.gastro.2009.09.006 Sangro, 2011, European network on radioembolization with yttrium-90 resin microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation, Hepatology, 54, 868, 10.1002/hep.24451 Vilgrain, 2017, Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial, Lancet Oncol, 18, 1624, 10.1016/S1470-2045(17)30683-6 Chow, 2018, SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma, J Clin Oncol, 36, 1913, 10.1200/JCO.2017.76.0892 Ricke, 2019, Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma, J Hepatol, 71, 1164, 10.1016/j.jhep.2019.08.006 Garin, 2018, Negative phase 3 study of 90Y microspheres versus sorafenib in HCC, Lancet Oncol, 19, e70, 10.1016/S1470-2045(18)30024-X Garin, 2016, Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in radioembolization of liver malignancies with 90Y-loaded microspheres, Eur J Nucl Med Mol Imaging, 43, 559, 10.1007/s00259-015-3157-8 Garin, 2012, Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT based dosimetry accurately predicts tumour response and survival in hepatocellular patients treated with 90Y-loaded glass microspheres: preliminary results, J Nucl Med, 53, 255, 10.2967/jnumed.111.094235 Garin, 2017, High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microsphere radioembolization, Liver Int, 37, 101, 10.1111/liv.13220 Garin, 2013, Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept, Eur J Nucl Med Mol Imaging, 40, 1057, 10.1007/s00259-013-2395-x Garin, 2015, Personalized dosimetry and intensification concept with 90Y-loaded glass microsphere radioembolization induce prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis, J Nucl Med, 56, 339, 10.2967/jnumed.114.145177 Garin, 2019, 90Y-loaded microsphere SIRT of HCC patients with portal vein thrombosis: high clinical impact of 99mTc-MAA SPECT/CT-based dosimetry, Semin Nucl Med, 49, 218, 10.1053/j.semnuclmed.2019.01.006 Forner, 2009, Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?, Cancer, 115, 616, 10.1002/cncr.24050 Harrison, 2009, MedDRA: the tale of a terminology: side effects of drugs essay, 33, 10.1016/S0378-6080(09)03160-2 Sangro, 2008, Liver disease induced by radioembolization of liver tumors: description and possible risk factors, Cancer, 112, 1538, 10.1002/cncr.23339 Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control Clin Trials, 17, 343, 10.1016/0197-2456(96)00075-X Kadalayil, 2013, A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer, Ann Oncol, 24, 2565, 10.1093/annonc/mdt247 Hopkins, 2019, Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors, Semin Oncol, 46, 380, 10.1053/j.seminoncol.2019.10.002 Joseph, 2018, Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab, Clin Cancer Res, 24, 4960, 10.1158/1078-0432.CCR-17-2386 Bruix, 2012, Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial, J Hepatol, 57, 821, 10.1016/j.jhep.2012.06.014 Edeline, 2020, Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial, JAMA Oncol, 6, 51, 10.1001/jamaoncol.2019.3702 Salem, 2019, Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group, Eur J Nucl Med Mol Imaging, 46, 1695, 10.1007/s00259-019-04340-5 Vouche, 2014, Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy, Hepatology, 60, 192, 10.1002/hep.27057 Hermann, 2020, Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH Study, Radiology, 290, 673, 10.1148/radiol.2020191606